||This article needs additional citations for verification. (December 2009)|
|Systematic (IUPAC) name|
|Licence data||EMA:, US FDA:|
|Pregnancy cat.||C (US)|
|Mol. mass||505.628 g/mol|
|(what is this?)|
Amprenavir (Agenerase, GlaxoSmithKline) is a protease inhibitor used to treat HIV infection. It was approved by the Food and Drug Administration on April 15, 1999, for twice-a-day dosing instead of needing to be taken every eight hours. The convenient dosing came at a price, as the dose required is 1,200 mg, delivered in eight very large gel capsules.
Production of amprenavir was discontinued by the manufacturer December 31, 2004; a prodrug version (fosamprenavir) is available.